CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+7.53%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$162M
(+18%)
Cap. Flow
+$137M
Cap. Flow
% of AUM
12.79%
Top 10 Holdings %
Top 10 Hldgs %
37.33%
Holding
532
New
105
Increased
323
Reduced
47
Closed
36
Top Buys
| 1 |
Apple
AAPL
|
+$9.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$7.06M |
| 3 |
NVIDIA
NVDA
|
+$6.46M |
| 4 |
Microsoft
MSFT
|
+$6.23M |
| 5 |
ProShares Ultra Gold
UGL
|
+$5.73M |
Top Sells
| 1 |
Alibaba
BABA
|
+$5.72M |
| 2 |
GSK
GSK
|
+$5.14M |
| 3 |
Pinduoduo
PDD
|
+$3.46M |
| 4 |
Procter & Gamble
PG
|
+$2.91M |
| 5 |
Synopsys
SNPS
|
+$2.45M |
Sector Composition
| 1 | Technology | 38.06% |
| 2 | Healthcare | 25.43% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Communication Services | 10.24% |
| 5 | Financials | 3.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
Ironwood Pharmaceuticals
IRWD
$180M
| $150K | 0.01% |
33,932
+3,209
| +10% | +$14.2K |
|
352
Tyra Biosciences
TYRA
$630M
| $149K | 0.01% |
+10,730
| New | +$149K |
|
353
Goodyear
GT
$2.45B
| $149K | 0.01% |
+16,500
| New | +$149K |
|
354
Evolus
EOLS
$478M
| $148K | 0.01% |
13,426
+1,291
| +11% | +$14.3K |
|
355
Relay Therapeutics
RLAY
$702M
| $146K | 0.01% |
35,491
+9,740
| +38% | +$40.1K |
|
|
TECX
356
Tectonic Therapeutic, Inc. Common Stock
TECX
$322M
| $144K | 0.01% |
+3,128
| New | +$144K |
|
|
ORKA
357
Oruka Therapeutics, Inc. Common Stock
ORKA
$601M
| $144K | 0.01% |
+7,421
| New | +$144K |
|
358
Kura Oncology
KURA
$695M
| $144K | 0.01% |
16,489
+1,750
| +12% | +$15.2K |
|
|
CRGX
359
DELISTED
CARGO Therapeutics
CRGX
| $141K | 0.01% |
+9,760
| New | +$141K |
|
360
Humacyte
HUMA
$238M
| $138K | 0.01% |
27,282
+4,327
| +19% | +$21.9K |
|
|
RAPP
361
Rapport Therapeutics
RAPP
$1.02B
| $138K | 0.01% |
+7,756
| New | +$138K |
|
362
Entrada Therapeutics
TRDA
$196M
| $137K | 0.01% |
+7,931
| New | +$137K |
|
363
Keros Therapeutics
KROS
$638M
| $136K | 0.01% |
8,589
+1,372
| +19% | +$21.7K |
|
|
MESO
364
Mesoblast
MESO
$1.92B
| $134K | 0.01% |
+6,776
| New | +$134K |
|
365
Skechers
SKX
$9.51B
| $133K | 0.01% |
1,985
-16,162
| -89% | -$1.09M |
|
366
Arbutus Biopharma
ABUS
$830M
| $131K | 0.01% |
40,179
+3,870
| +11% | +$12.7K |
|
|
BCYC
367
Bicycle Therapeutics
BCYC
$493M
| $131K | 0.01% |
9,329
+2,191
| +31% | +$30.7K |
|
368
Mineralys Therapeutics
MLYS
$2.99B
| $130K | 0.01% |
10,553
+989
| +10% | +$12.2K |
|
|
GRAL
369
GRAIL, Inc. Common Stock
GRAL
$1.35B
| $127K | 0.01% |
7,125
+1,153
| +19% | +$20.6K |
|
370
Stoke Therapeutics
STOK
$1.21B
| $124K | 0.01% |
+11,231
| New | +$124K |
|
371
Schrodinger
SDGR
$1.43B
| $124K | 0.01% |
6,410
| – | – |
|
372
Futu Holdings
FUTU
$26.2B
| $123K | 0.01% |
1,414
-5,880
| -81% | -$512K |
|
373
Omeros
OMER
$290M
| $121K | 0.01% |
+12,287
| New | +$121K |
|
374
Oric Pharmaceuticals
ORIC
$1.06B
| $121K | 0.01% |
14,963
+1,395
| +10% | +$11.3K |
|
375
Phathom Pharmaceuticals
PHAT
$914M
| $118K | 0.01% |
14,499
+1,365
| +10% | +$11.1K |
|